Abbott Laboratories
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting bottom-line expectations for earnings per share, the healthcare giant reported a significant revenue miss that spooked investors, driven primarily by
Medtronic
New York, NY – November 20, 2025 – UBS Group has adjusted its outlook on Medtronic plc (NYSE: MDT) stock, raising its price target to $102.00 from $95.00. This upward revision follows Medtronic's stronger-than-expected second-quarter fiscal 2026 earnings report, which showcased robust performance driven by key segments and
Healthcare
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an uncertain economic landscape. While specific real-time data for this future date is beyond current predictive capabilities, an analysis of the
NASDAQ
November 5, 2025 – NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has been granted a crucial 180-day extension by Nasdaq, providing a temporary reprieve from potential delisting. This development, announced today, comes as the medical device company grapples with its common stock trading below the exchange's mandated minimum bid price
Beyond Air
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company at the forefront of nitric oxide (NO) therapies, announced on November 5, 2025, a significant financing deal of up to $32 million with Streeterville Capital. This strategic financial infusion, comprising a $12 million promissory note and a $20 million
Douglas Emmett
The financial markets are a constant ebb and flow, and recently, the tide has pulled several prominent companies down to their 52-week lows. Among them, real estate investment trust Douglas Emmett (NYSE: DEI) and medical device giant Zimmer Biomet Holdings, Inc. (NYSE: ZBH) stand out. Their recent stock performance reflects
Integer Holdings
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares plummeting a staggering 31.4%. The significant sell-off came despite the company reporting strong third-quarter 2025 earnings that largely met or exceeded
Intuitive Surgical
Intuitive Surgical (NASDAQ: ISRG), the global leader in robotic-assisted surgery, announced a robust third quarter for 2025, sending its stock soaring as investors cheered impressive financial results and strong adoption of its latest da Vinci 5 surgical system. The company's report, released on October 21, 2025, showcased significant
Boston Scientific
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to
Inspire Medical Systems
Minneapolis, MN – October 13, 2025 – Inspire Medical Systems (NYSE: INSP) emerged as a standout performer in today's trading session, witnessing its stock price jump by an impressive 3.9% by the closing bell. This significant surge is primarily attributed to the overwhelmingly positive clinical outcomes data presented for
Merit Medical Systems
Merit Medical Systems (NASDAQ: MMSI) has announced a significant milestone for its SCOUT Radar Localization technology, which has now been utilized in over 750,000 patient procedures worldwide. This achievement, coinciding with Breast Cancer Awareness Month, underscores the widespread adoption and critical impact of the wire-free, non-radioactive localization device in
Healthcare
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government shutdown and a disappointing jobs report. As investors sought refuge in defensive plays and reacted to